1. Home
  2. RGEN vs DLB Comparison

RGEN vs DLB Comparison

Compare RGEN & DLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Repligen Corporation

RGEN

Repligen Corporation

HOLD

Current Price

$156.66

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Logo Dolby Laboratories

DLB

Dolby Laboratories

HOLD

Current Price

$67.61

Market Cap

6.4B

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGEN
DLB
Founded
1981
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Multi-Sector Companies
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
8.2B
6.4B
IPO Year
N/A
2005

Fundamental Metrics

Financial Performance
Metric
RGEN
DLB
Price
$156.66
$67.61
Analyst Decision
Buy
Strong Buy
Analyst Count
10
5
Target Price
$170.90
$93.60
AVG Volume (30 Days)
696.6K
653.1K
Earning Date
10-28-2025
01-28-2026
Dividend Yield
N/A
2.13%
EPS Growth
N/A
N/A
EPS
0.03
2.62
Revenue
$707,890,000.00
$1,349,130,000.00
Revenue This Year
$17.84
$5.03
Revenue Next Year
$12.57
$4.02
P/E Ratio
$6,185.26
$25.82
Revenue Growth
11.74
5.92
52 Week Low
$102.97
$64.02
52 Week High
$182.52
$89.66

Technical Indicators

Market Signals
Indicator
RGEN
DLB
Relative Strength Index (RSI) 47.50 53.05
Support Level $160.11 $66.09
Resistance Level $165.02 $68.84
Average True Range (ATR) 4.97 1.17
MACD -1.27 0.22
Stochastic Oscillator 7.12 52.04

Price Performance

Historical Comparison
RGEN
DLB

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About DLB Dolby Laboratories

Dolby Laboratories Inc. develops technologies that enhance audio and video capture, transmission, and playback, enabling high-quality experiences across movies, TV, music, sports, and more. The company designs and manufactures audio, imaging, accessibility, and related hardware and software mainly for cinema, including digital cinema servers and media encryption and packaging tools. It generates the majority of its revenue by licensing its technology, brand, and patents to device manufacturers and by selling cinema hardware and services. It operates as a single reportable segment, with revenue derived mainly from licensing and, to a lesser extent, from premium cinema technologies, across the United States and international markets.

Share on Social Networks: